<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03647657</url>
  </required_header>
  <id_info>
    <org_study_id>2018-00972</org_study_id>
    <nct_id>NCT03647657</nct_id>
  </id_info>
  <brief_title>177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer</brief_title>
  <official_title>177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer (Lumed Phase 0/B)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Krebsforschung Schweiz, Bern, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Center for Proton Therapy, Paul Scherrer Institute, Villigen,Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Zürich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Freiburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the use of 177Lu-PP-F11N for imaging and therapy of
      patients with advanced medullary thyroid carcinoma (MTC). 177Lu-PP-F11N is a gastrin
      analogon, binding to cholecystokinin-2 receptors. This receptors show an overexpression on
      more than 90 % of medullary thyroid carcinomas.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase 0 study (Lumed study part A) was already performed, showing low toxicity of
      177Lu-PP-F11N and tumor uptake in all patients. Co-injection of Physiogel (Gelofusin) showed
      insignificant reduction of kidney uptake and can therefore be omitted for a radionuclide
      therapy with 177Lu-PP-F11N. In this study, the effect of the NEP-1 inhibitor Sacuitril on the
      in-vivo stability of 177Lu-PP-F11N and the uptake, respectively radiation doses in MTC
      metastases and organs will be evaluated, using a cross-over design already used for the Lumed
      part A study. Each patient will receive two injections of 177Lu-PP-F11N, with and without
      additional medication with Sacuitril Imaging findings, acquired by SPECT/CT, will be compared
      to imaging with 68Ga-DOTATOC positron emission tomography (PET)/CT. The inclusion of 8
      patients is planned.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 13, 2018</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Group 1 patients will receive first 177Lu-PP-F11N alone, second 177Lu-PP-F11N in combination with Sacuitril. Group 2 patients will first receive 177Lu-PP-F11N in combination with Sacuitril, second 177Lu-PP-F11N alone. Affiliation of patients to Groups 1 and 2 will be randomised.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>No masking</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor radiation doses</measure>
    <time_frame>Measurement up to 72 hours after each injection of 177Lu-PP-F11N</time_frame>
    <description>Evaluation of the radiation doses in tumor tissue from MTC after injection of 177Lu-PP-F11N alone and in combination with Sacuitril (Entresto)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kidney radiation doses</measure>
    <time_frame>Measurement up to 72 hours after each injection of 177Lu-PP-F11N</time_frame>
    <description>Evaluation of the radiation doses in the kidneys and the tumor-to-kidney dose ratios after injection of 177Lu-PP-F11N alone and in combination with Sacuitril (Entresto)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ radiation doses</measure>
    <time_frame>Measurement up to 72 hours after each injection of 177Lu-PP-F11N</time_frame>
    <description>Evaluation of the radiation doses in other organs and the appropriate organ-to-kidney dose ratios after injection of 177Lu-PP-F11N alone and in combination with Sacuitril (Entresto)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-vivo stability</measure>
    <time_frame>Blood samples for measurement 5 and 30 minutes post injection of 177Lu-PP-F11N</time_frame>
    <description>Measurement (HPLC) of the in-vivo stability of 177Lu-PP-F11N alone and in combination with Sacuitril (Entresto).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autoradiography</measure>
    <time_frame>Through study completion, up to 18 months</time_frame>
    <description>In case of surgery with available tumor tissue samples, imaging results will be compared with autoradiographic analysis of somatostatine- and CCK2-receptor expression in tumor tissue.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Chromogranin A</measure>
    <time_frame>Measurement up to 72 hours after the first injection of 177Lu-PP-F11N</time_frame>
    <description>Chromogranin A blood values will be compared to the radiation doses of the stomach.</description>
  </other_outcome>
  <other_outcome>
    <measure>68Ga-DOTATOC PET/CT</measure>
    <time_frame>Measurement up to 72 hours after each injection of 177Lu-PP-F11N</time_frame>
    <description>Comparison of tumor imaging by 68Ga-DOTATOC PET/CT and 177Lu-PP-F11N SPECT/CT</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Thyroid Cancer, Medullary</condition>
  <arm_group>
    <arm_group_label>Entresto second</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First intravenous application of 2 x 1 gigabequerel (GBq) 177Lu-PP-F11N without and second injection with additional medication of Sacuitril (100 mg Entresto)(crossover)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Entresto first</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First intravenous application of 2 x 1 gigabequerel (GBq) 177Lu-PP-F11N with and second injection without additional medication of Sacuitril (100 mg Entresto)(crossover)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>177Lu-PP-F11N</intervention_name>
    <description>Intravenous application of 2 x 1 gigabequerel (GBq) 177Lu-PP-F11N with and without co-medication with Sacuitril (100 mg Entresto) in each patient</description>
    <arm_group_label>Entresto first</arm_group_label>
    <arm_group_label>Entresto second</arm_group_label>
    <other_name>Radiopharmakon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sacuitril</intervention_name>
    <description>Medication with Sacuitril (100 mg Entresto) additional to the injection of 177Lu-PP-F11N</description>
    <arm_group_label>Entresto first</arm_group_label>
    <arm_group_label>Entresto second</arm_group_label>
    <other_name>Entresto</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced MTC with elevated levels of calcitonin (&gt; 100 pg/ml) and/or
             calcitonin-doubling time &lt; 24 months before or after total thyroidectomy

          -  68Ga-DOTATOC PET/CT not older than 12 weeks

          -  Age &gt; 18 years

          -  Informed consent

        Exclusion Criteria:

          -  Medication with Vandetanib 3 weeks before the study and during the study

          -  Renal failure (calculated glomerular filtration rate (GFR) &lt; 60 ml/min per 1.73 m2
             body surface).

          -  Bone marrow failure (thrombocytes &lt; 70 000/μl, leucocytes &lt; 2 500/μl, hemoglobin &lt; 8
             g/dl).

          -  Pregnancy and breast feeding

          -  Known, serious side reaction in the case of a former application of pentagastrin

          -  Active, second malignancy oder remission after second malignancy &lt; 5 years

          -  Age over 64 years

          -  Systolic bood pressure &lt; 112 mmHg at the time of screening

          -  Simultaneous medication with angiotensin converting enzyme (ACE)-inhibitors, or
             withdrawal for less than 36 h prior to the medication with Entresto or simultaneous
             medication with AT-II-receptor blockers

          -  Known intolerance to Sacubitril or Valsartan

          -  Known angioedema in anamnesis in the context of a medication with an ACE-inhibitor or
             an AT-II-receptor blocker
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christof Rottenburger, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Basel, Clinic for radiology and nuclear medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Damian Wild, PhD Dr</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital Basel, Clinic for radiology and nuclear medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christof Rottenburger, Dr. med.</last_name>
    <phone>0041613286551</phone>
    <email>christof.rottenburger@usb.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Damian Wild, PhD Dr</last_name>
    <phone>0041613286683</phone>
    <email>damian.wild@usb.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Basel, Clinic for radiology and nuclear medicine</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christof Rottenburger, Dr. med.</last_name>
      <phone>0041613286551</phone>
      <email>christof.rottenburger@ubs.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>https://www.unispital-basel.ch/en</url>
    <description>University Hospital Basel Homepage</description>
  </link>
  <results_reference>
    <citation>Sauter AW, Mansi R, Hassiepen U, Muller L, Panigada T, Wiehr S, Wild AM, Geistlich S, Béhé M, Rottenburger C, Wild D, Fani M. Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog (177)Lu-DOTA-PP-F11N: Does the Use of Protease Inhibitors Further Improve In Vivo Distribution? J Nucl Med. 2019 Mar;60(3):393-399. doi: 10.2967/jnumed.118.207845. Epub 2018 Jul 12.</citation>
    <PMID>30002107</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 20, 2018</study_first_submitted>
  <study_first_submitted_qc>August 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2018</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Calcitonin</keyword>
  <keyword>Medullary thyroid carcinoma</keyword>
  <keyword>Peptide receptor radionuclide therapy</keyword>
  <keyword>Gastrin</keyword>
  <keyword>Cholecystokinin-2 receptor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>LCZ 696</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

